A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction

The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction

开始日期2024-02-13

申办/合作机构

Cardurion Pharmaceuticals, Inc.

NCT06215911

/ Completed临床2期

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with reduced ejection fraction.

开始日期2024-02-13

申办/合作机构

Cardurion Pharmaceuticals, Inc.

NCT05312021

/ Withdrawn临床2期

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction: a Safety and Efficacy Phase 2 Randomized Clinical Study (SP9In-HFpEF)

This study is to evaluate whether 16 weeks of treatment with IMR-687 is a safe and effective treatment for patients with Heart Failure with Preserved Ejection Fraction (HFpEF). The primary objective is to evaluate whether IMR-687 reduces NT-proBNP compared to placebo in these patients.

开始日期2022-04-01

申办/合作机构

Cardurion Pharmaceuticals, Inc.

[+1]

100 项与 Tovinontrine 相关的临床结果

登录后查看更多信息

100 项与 Tovinontrine 相关的转化医学

登录后查看更多信息

100 项与 Tovinontrine 相关的专利（医药）

登录后查看更多信息

项与 Tovinontrine 相关的文献（医药）

2021-12-10·Hematology. American Society of Hematology. Education Program3区 · 教育学

β-Thalassemia: evolving treatment options beyond transfusion and iron chelation

3区 · 教育学

Review

作者: Langer, Arielle L. ; Esrick, Erica B.

Abstract:

After years of reliance on transfusion alone to address anemia and suppress ineffective erythropoiesis in β-thalassemia, many new therapies are now in development. Luspatercept, a transforming growth factor–β inhibitor, has demonstrated efficacy in reducing ineffective erythropoiesis, improving anemia, and possibly reducing iron loading. However, many patients do not respond to luspatercept, so additional therapeutics are needed. Several medications in development aim to induce hemoglobin F (HbF): sirolimus, benserazide, and IMR-687 (a phosphodiesterase 9 inhibitor). Another group of agents seeks to ameliorate ineffective erythropoiesis and improve anemia by targeting abnormal iron metabolism in thalassemia: apotransferrin, VIT-2763 (a ferroportin inhibitor), PTG-300 (a hepcidin mimetic), and an erythroferrone antibody in early development. Mitapivat, a pyruvate kinase activator, represents a unique mechanism to mitigate ineffective erythropoiesis. Genetically modified autologous hematopoietic stem cell transplantation offers the potential for lifelong transfusion independence. Through a gene addition approach, lentiviral vectors have been used to introduce a β-globin gene into autologous hematopoietic stem cells. One such product, betibeglogene autotemcel (beti-cel), has reached phase 3 trials with promising results. In addition, 2 gene editing techniques (CRISPR-Cas9 and zinc-finger nucleases) are under investigation as a means to silence BCL11A to induce HbF with agents designated CTX001 and ST-400, respectively. Results from the many clinical trials for these agents will yield results in the next few years, which may end the era of relying on transfusion alone as the mainstay of thalassemia therapy.

2021-08-01·American journal of hematology

SARS‐CoV‐2 infection in patients with β‐thalassemia: Experience from Lebanon

Letter

作者: Noun, Peter ; Abou Nasr, Therese ; Bou‐Fakhredin, Rayan ; Koussa, Suzanne ; Taher, Ali T. ; Daadaa, Hisham

In this report, severity of Covid-19 was investigated among β-thalassemia patients who are regularly followed up at the Chronic Care Center (CCC), tertiary care thalassemia center in Lebanon.Patients' clin. characteristics, Covid-19 signs and symptoms, treatment, disease course and outcomes were collected by analyzing patients' medical records and by directly calling the patients and checking on their well-being.The comorbidities present among our β-thalassemia patients are reported in the Table S1.Overall, 37 (92.5%) patients had at least one comorbidity. Most of our patients suffered from iron overload.Liver iron concentration (LIC) (mg/g) was classified as: mild (LIC 3-7 mg/g), moderate (LIC >7-14 mg/g), and severe overload (LIC >15 mg/g).In our patient cohort 13 (32.5%) patients had mild iron overload, seven (20.6%) patients had moderate iron overload, and six (17.6%) patient had severe iron overload. Eight patients never had their LIC determinedTwenty six patients (65%) were splenectomized.Of the 26 splenectomized patients, 19/26 (73.1%) were on aspirin, 1/26 (3.8%) was on warfarin for his co-existing atrial fibrillation, and 3/26 (11.5%) were switched to low mol. weight heparin (enoxaparin) in the hospital setting.

项与 Tovinontrine 相关的新闻（医药）

2026-09-20

·BioSpace

HFSA’s 2026 Annual Scientific Meeting to Feature Late-Breaking Trials That Could Reshape Heart Failure Treatment

October 9-12, 2026 | Phoenix, Arizona -- New data spans pharmacotherapy, imaging and diagnostics, and device therapy for patients with cardiomyopathy WASHINGTON , Sept. 18, 2026 / PRNewswire / -- The Heart Failure Society of America ( HFSA ) today announced the Late-Breaking Clinical Research slate for its Annual Scientific Meeting ( ASM ), October 9-12, 2026, at the Phoenix Convention Center in Phoenix, Arizona. This year's late-breaking program spans pharmacotherapy, imaging and diagnostics, and device-based therapy - including new data on whether a novel oral therapy could establish an additional treatment pillar for both HFrEF and HFpEF , a first-of-its-kind imaging approach designed to detect cardiac amyloidosis without an invasive biopsy, and real-world outcomes from established device therapies. View all late-breaking science below and online . These trials ... represent some of the most anticipated data in ... medicine for patients with cardiomyopathy this year. "This year's Late-Breaking Science program reflects the pace of innovation transforming heart failure care," said Jennifer Thibodeau , MD, MSCS , 2026 HFSA Annual Scientific Meeting Program Committee Chair. "These trials showcase advances in pharmacotherapy, imaging and diagnostics, as well as device therapy, and represent some of the most anticipated data in cardiovascular medicine for patients with cardiomyopathy this year." Late-breaking clinical research to be featured during two plenary sessions includes results and updates from these major randomized trials: Sunday, October 11 Plenary Session | 9:00 AM – 10:30 AM Late-Breaking Evidence from Novel Therapies to Real-World Outcomes Cycle-1 REF A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction: The Cycle-1 REF Trial Cycle-2 PEF A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction: The Cycle-2 PEF Trial CARDIO- TTRansform Effect of Eplontersen on Health Status in Patients with Transthyretin Amyloid Cardiomyopathy Enrolled in the CARDIO- TTRansform Trial 124I- Evuzamitide Amyloid-targeted PET/CT Scan: Potential for Detection of Early Cardiac Amyloidosis in a Prospective Multicenter Phase 3 Study Cohort Cardiac Contractility Modulation Therapy One-Year Real-World Clinical Outcomes Following Cardiac Contractility Modulation Therapy from the U.S. Post-Approval Study REBALANCE The REBALANCE Registry: Real World Outcomes Following Baroreflex Activation Therapy Monday, October 12 Plenary Session | 9:00 AM – 10:30 AM Late-Breaking Evidence from Novel Therapies to Real-World Outcomes ACACIA- HCM Global Efficacy Of Aficamten In Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA- HCM Aficamten Improves Comprehensive Measures of Exercise Performance in Non-Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of ACACIA- HCM POSEIDON Prevalence of Cardiovascular Inflammation and Associated Patient Characteristics and Biomarker Profiles Across the Heart Failure Spectrum in the United States: Results From the POSEIDON Study C-MIC III & C-MIC II Effects of Cardiac Microcurrent Therapy on Exercise Capacity: Independent Core Laboratory CPET Analysis of the C-MIC II Trial Six-Month Outcomes of Subcutaneous Cardiac Microcurrent Therapy: Comparative Analysis of the C-MIC III Pilot Study with the C-MIC II Randomized Trial Late-breaking clinical research showcases novel results of major randomized trials and rapidly evolving research. Due to the exceptional volume and quality of research submitted this year, HFSA will also feature late-breaking research through Rapid Fire Oral Sessions. These Rapid Fire sessions are fast-paced oral presentations spotlighting key data from late breaking clinical research. Sessions take place on Sunday and Monday with Q&A and new topics each day. Sunday, October 11 | Rapid Fire 1 | 10:45 AM - 11:45 AM Ratio of Serum Transthyretin to NT- proBNP is a Novel Prognostic Measure for Transthyretin Amyloid Cardiomyopathy: Insights From ATTRibute -CM Colchicine In Patients With Heart Failure And Preserved Ejection Fraction: A Crossover Trial The ReDS -SAFE HF II: Remote Dielectric Sensing-Guided Decongestion Strategy In Patients Hospitalized For Heart Failure. A Trial Design Early eGFR Decline Following Acoramidis Initiation is Associated With Reduced Risk of Recurrent Cardiovascular Hospitalizations and Mortality Gator SCALES- WHF : Sub-Cutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure Real World Comparative Effectiveness Study of Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy Using the Epic COSMOS Data Platform Dosing And Safety Of Aficamten For Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy In The ACACIA- HCM Trial Sunday, October 11 | Rapid Fire 2 | 2:30 PM - 3:30 PM Ambulatory Upright Pulmonary Artery Pressure and Risk of HF Hospitalization and Death in Patients with Chronic Heart Failure Hyperbaric Oxygen Therapy and EECP as Adjuvant Therapy in Heart Failure : A Prospective Interventional Study Baroreflex Activation Therapy in Heart Failure with Mildly Reduced Ejection Fraction: First Real-World Evidence of Reduced Hospitalization Burden Cost-Effectiveness Of ReDS -Guided Heart Failure Management Pulmonary Artery Pressure Response to Loop and Thiazide Diuretic Intensification in Heart Failure: Impact of Diuretic Class and Patient Characteristics Ambient Home Monitoring of Peripheral Oedema Significantly Reduces Heart Failure Events: Final Results from the Randomized HF-TRACK Trial Therapeutic Sequencing Is Projected to Improve Quality-Adjusted Survival in Heart Transplant Candidates with Advanced Heart Failure: A Risk-Selected Left Ventricular Assist Device-First Strategy Sunday, October 11 | Rapid Fire 3 | 5:00 PM - 6:00 PM Impact of Eplontersen on Cardiac Biomarkers in Participants with Transthyretin Amyloid Cardiomyopathy in the CARDIO- TTRansform Phase III Trial Weight Loss Surgery Impact on Comprehensive Metabolic Responses to Exercise in Heart Failure with Preserved Ejection Fraction Primary Results Trajectories of Dyspnea After Heart Failure Hospitalization: A Prospective Longitudinal Cohort Study Achieving Near Target-Dose Quadruple Guideline-Directed Medical Therapy Before Hospital Discharge After Acute Heart Failure: The STRONG-HF Japan Study Association of Quadruple Therapy Achievement and Biochemically Verified Medication Adherence with Outcomes in HFrEF : Insights from the POLY-HF Trial The Impact Of An Adaptive Patient-Centered Web Application on Medication Optimization In Patients With HFrEF : A Multicenter Randomized Trial Monday, October 12 | Rapid Fire 4 | 12:15 PM – 1:15 PM TAILORD Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients with Heart Failure Post-ARIES Antithrombotic Implementation and Safety Evaluation in HeartMate 3 (PRAISE HM-3) EDG -15400, A Cardiac Sarcomere Modulator, Demonstrated Favorable Pharmacokinetics , Pharmacodynamics , and Tolerability in Healthy Adult Participants Rapid Non-invasive Sensors-Derived Assessment of Left Ventricular Filling Pressure in Patients Presenting With Acute Dyspnea Three-Year Results of PROACTIVE-HF Trial Stratified by Sex The meeting kicks off in just three weeks. A full schedule-at-a-glance is available online , as well as information on the science and research available at the meeting. Learn more about the meeting and register at hfsa .org/ asm 2026 . Media Registration & Embargo Policy Credentialed and accredited media may register for complimentary press access to HFSA ASM 2026 by contacting Laura Poko at lpoko @ hfsa .org. As part of HFSA's 24-Hour Press Access Window, credentialed and accredited media will receive embargoed access to press materials beginning 24 hours before each embargo lifts. During this period, media may review embargoed press releases, abstracts, and presenter details via a secure, password-protected folder, and schedule pre -embargo interviews with late-breaking science presenters. All interviews and materials remain strictly embargoed until the time of presentation listed above. Follow # HFSA 2026 for real-time coverage from the meeting. About the Heart Failure Society of America The Heart Failure Society of America, Inc. ( HFSA ) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure ( CHF ) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa .org . Media Contact : Laura Poko , 301-798-4493, ext. 226, lpoko @ hfsa .org View original content to download multimedia: SOURCE Heart Failure Society of America

临床3期临床2期

2026-09-18

·PRNewswire

HFSA's 2026 Annual Scientific Meeting to Feature Late-Breaking Trials That Could Reshape Heart Failure Treatment

October 9-12, 2026 | Phoenix, Arizona -- New data spans pharmacotherapy, imaging and diagnostics, and device therapy for patients with cardiomyopathy Continue Reading These trials ... represent some of the most anticipated data in ... medicine for patients with cardiomyopathy this year. Post this The HFSA Annual Scientific Meeting takes place October 9-12, 2026 in Phoenix, Arizona. WASHINGTON, Sept. 18, 2026 /PRNewswire/ -- The Heart Failure Society of America (HFSA) today announced the Late-Breaking Clinical Research slate for its Annual Scientific Meeting (ASM), October 9-12, 2026, at the Phoenix Convention Center in Phoenix, Arizona. This year's late-breaking program spans pharmacotherapy, imaging and diagnostics, and device-based therapy - including new data on whether a novel oral therapy could establish an additional treatment pillar for both HFrEF and HFpEF, a first-of-its-kind imaging approach designed to detect cardiac amyloidosis without an invasive biopsy, and real-world outcomes from established device therapies. View all late-breaking science below and online. "This year's Late-Breaking Science program reflects the pace of innovation transforming heart failure care," said Jennifer Thibodeau, MD, MSCS, 2026 HFSA Annual Scientific Meeting Program Committee Chair. "These trials showcase advances in pharmacotherapy, imaging and diagnostics, as well as device therapy, and represent some of the most anticipated data in cardiovascular medicine for patients with cardiomyopathy this year." Late-breaking clinical research to be featured during two plenary sessions includes results and updates from these major randomized trials: Sunday, October 11 Plenary Session | 9:00 AM – 10:30 AM Late-Breaking Evidence from Novel Therapies to Real-World Outcomes Cycle-1 REF A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction: The Cycle-1 REF Trial Cycle-2 PEF A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction: The Cycle-2 PEF Trial CARDIO-TTRansform Effect of Eplontersen on Health Status in Patients with Transthyretin Amyloid Cardiomyopathy Enrolled in the CARDIO-TTRansform Trial 124I-Evuzamitide Amyloid-targeted PET/CT Scan: Potential for Detection of Early Cardiac Amyloidosis in a Prospective Multicenter Phase 3 Study Cohort Cardiac Contractility Modulation Therapy One-Year Real-World Clinical Outcomes Following Cardiac Contractility Modulation Therapy from the U.S. Post-Approval Study REBALANCE The REBALANCE Registry: Real World Outcomes Following Baroreflex Activation Therapy Monday, October 12 Plenary Session | 9:00 AM – 10:30 AM Late-Breaking Evidence from Novel Therapies to Real-World Outcomes ACACIA-HCM Global Efficacy Of Aficamten In Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM Aficamten Improves Comprehensive Measures of Exercise Performance in Non-Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of ACACIA-HCM POSEIDON Prevalence of Cardiovascular Inflammation and Associated Patient Characteristics and Biomarker Profiles Across the Heart Failure Spectrum in the United States: Results From the POSEIDON Study C-MIC III & C-MIC II Effects of Cardiac Microcurrent Therapy on Exercise Capacity: Independent Core Laboratory CPET Analysis of the C-MIC II Trial Six-Month Outcomes of Subcutaneous Cardiac Microcurrent Therapy: Comparative Analysis of the C-MIC III Pilot Study with the C-MIC II Randomized Trial Late-breaking clinical research showcases novel results of major randomized trials and rapidly evolving research. Due to the exceptional volume and quality of research submitted this year, HFSA will also feature late-breaking research through Rapid Fire Oral Sessions. These Rapid Fire sessions are fast-paced oral presentations spotlighting key data from late breaking clinical research. Sessions take place on Sunday and Monday with Q&A and new topics each day. Sunday, October 11 | Rapid Fire 1 | 10:45 AM - 11:45 AM Ratio of Serum Transthyretin to NT-proBNP is a Novel Prognostic Measure for Transthyretin Amyloid Cardiomyopathy: Insights From ATTRibute-CM Colchicine In Patients With Heart Failure And Preserved Ejection Fraction: A Crossover Trial The ReDS-SAFE HF II: Remote Dielectric Sensing-Guided Decongestion Strategy In Patients Hospitalized For Heart Failure. A Trial Design Early eGFR Decline Following Acoramidis Initiation is Associated With Reduced Risk of Recurrent Cardiovascular Hospitalizations and Mortality Gator SCALES-WHF: Sub-Cutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure Real World Comparative Effectiveness Study of Acoramidis Versus Tafamidis in Transthyretin Amyloid Cardiomyopathy Using the Epic COSMOS Data Platform Dosing And Safety Of Aficamten For Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy In The ACACIA-HCM Trial Sunday, October 11 | Rapid Fire 2 | 2:30 PM - 3:30 PM Ambulatory Upright Pulmonary Artery Pressure and Risk of HF Hospitalization and Death in Patients with Chronic Heart Failure Hyperbaric Oxygen Therapy and EECP as Adjuvant Therapy in Heart Failure : A Prospective Interventional Study Baroreflex Activation Therapy in Heart Failure with Mildly Reduced Ejection Fraction: First Real-World Evidence of Reduced Hospitalization Burden Cost-Effectiveness Of ReDS-Guided Heart Failure Management Pulmonary Artery Pressure Response to Loop and Thiazide Diuretic Intensification in Heart Failure: Impact of Diuretic Class and Patient Characteristics Ambient Home Monitoring of Peripheral Oedema Significantly Reduces Heart Failure Events: Final Results from the Randomized HF-TRACK Trial Therapeutic Sequencing Is Projected to Improve Quality-Adjusted Survival in Heart Transplant Candidates with Advanced Heart Failure: A Risk-Selected Left Ventricular Assist Device-First Strategy Sunday, October 11 | Rapid Fire 3 | 5:00 PM - 6:00 PM Impact of Eplontersen on Cardiac Biomarkers in Participants with Transthyretin Amyloid Cardiomyopathy in the CARDIO-TTRansform Phase III Trial Weight Loss Surgery Impact on Comprehensive Metabolic Responses to Exercise in Heart Failure with Preserved Ejection Fraction Primary Results Trajectories of Dyspnea After Heart Failure Hospitalization: A Prospective Longitudinal Cohort Study Achieving Near Target-Dose Quadruple Guideline-Directed Medical Therapy Before Hospital Discharge After Acute Heart Failure: The STRONG-HF Japan Study Association of Quadruple Therapy Achievement and Biochemically Verified Medication Adherence with Outcomes in HFrEF: Insights from the POLY-HF Trial The Impact Of An Adaptive Patient-Centered Web Application on Medication Optimization In Patients With HFrEF: A Multicenter Randomized Trial Monday, October 12 | Rapid Fire 4 | 12:15 PM – 1:15 PM TAILORD Electronic Intervention to Improve Therapy in a Diverse Cohort of Patients with Heart Failure Post-ARIES Antithrombotic Implementation and Safety Evaluation in HeartMate 3 (PRAISE HM-3) EDG-15400, A Cardiac Sarcomere Modulator, Demonstrated Favorable Pharmacokinetics, Pharmacodynamics, and Tolerability in Healthy Adult Participants Rapid Non-invasive Sensors-Derived Assessment of Left Ventricular Filling Pressure in Patients Presenting With Acute Dyspnea Three-Year Results of PROACTIVE-HF Trial Stratified by Sex The meeting kicks off in just three weeks. A full schedule-at-a-glance is available online, as well as information on the science and research available at the meeting. Learn more about the meeting and register at hfsa.org/asm2026. Media Registration & Embargo Policy Credentialed and accredited media may register for complimentary press access to HFSA ASM 2026 by contacting Laura Poko at lpoko@hfsa.org. As part of HFSA's 24-Hour Press Access Window, credentialed and accredited media will receive embargoed access to press materials beginning 24 hours before each embargo lifts. During this period, media may review embargoed press releases, abstracts, and presenter details via a secure, password-protected folder, and schedule pre-embargo interviews with late-breaking science presenters. All interviews and materials remain strictly embargoed until the time of presentation listed above. Follow #HFSA2026 for real-time coverage from the meeting. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org. Media Contact: Laura Poko, 301-798-4493, ext. 226, lpoko@hfsa.org SOURCE Heart Failure Society of America 21% more press release views with Request a Demo

2026-08-27

·BioSpace

Cardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart Failure

Results from two Phase 2 clinical trials assessing tovinontrine in both major types of chronic heart failure will be presented at the Heart Failure Society of America annual scientific meeting BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Cardurion Pharmaceuticals , Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of patients with cardiovascular diseases, today announced that the Company will present results from the Phase 2 CYCLE clinical trials evaluating tovinontrine (CRD-750), a novel phosphodiesterase-9 (PDE9) inhibitor, in chronic heart failure. The results will be presented in late-breaking presentations at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Phoenix, Arizona taking place on October 9–12, 2026. Tovinontrine is an orally administered PDE9 inhibitor that represents a new mechanism to enhance the natriuretic peptide signaling (NPS) pathway, a clinically validated pathway for the treatment of patients with heart failure. Cardurion is the first company to bring a PDE9 inhibitor into clinical development for the treatment of chronic heart failure. “We look forward to sharing the exciting results from our CYCLE trials, which represent the first time that robust Phase 2 data have been completed for PDE9 inhibition in heart failure. Despite current standard of care, a large unmet medical need remains, and patients with chronic heart failure continue to experience high rates of morbidity and mortality,” said Howard Surks, MD, Chief Medical and Scientific Officer of Cardurion. “It is a major milestone for our company to successfully complete this large, global clinical program in both major types of heart failure, and the results of the CYCLE studies will guide the next stage of clinical development for tovinontrine as we move closer to our goal of bringing this novel PDE9 inhibitor to patients with chronic heart failure.” The presentations at HFSA in October will describe the results from Cardurion’s global, multi-center, Phase 2 clinical trials ( NCT06215911 and NCT06215586 ) assessing the safety and efficacy of tovinontrine in the two major types of chronic heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) . Details for the presentations at HFSA are as follows: CYCLE-1 REF presentation title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine (CRD-750) in Patients With Chronic Heart Failure With Reduced Ejection Fraction: The Cycle-1 REF Trial CYCLE-2 PEF presentation title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Assess the Safety and Effectiveness of Tovinontrine (CRD-750) in Patients With Chronic Heart Failure With Preserved Ejection Fraction: The Cycle-2 PEF Trial About PDE9 Inhibition Phosphodiesterase (PDE) 9 is an enzyme whose elevated activity in patients with heart failure reduces the beneficial effects of the natriuretic peptide signaling (NPS) pathway. The NPS pathway plays an important and protective role in cardiac function, and its activation has been shown to confer outcomes benefit for patients with heart failure . PDE9 is significantly upregulated in patients with chronic heart failure, causing disruption in the NPS pathway. Cardurion is the first company to demonstrate clinical proof-of-mechanism for PDE9 inhibition in patients with chronic heart failure with its PDE9 program. About Heart Failure Heart failure is a prevalent and growing condition that is responsible for substantial morbidity and mortality. Approximately 6.7 million adults in the United States suffer from heart failure, and approximately 50 percent of these patients die from the condition within five years of diagnosis. One in five patients with heart failure are hospitalized annually, and approximately 25 percent of these patients are re-admitted within a month of discharge. Approximately half of all patients with chronic heart failure have reduced ejection fraction (HFrEF) and half have preserved ejection fraction (HFpEF), categorized as different diseases based on the pumping ability of the heart. Significant unmet medical needs remain in heart failure, despite the reductions in morbidity and mortality from currently approved treatments for heart failure. About Cardurion Pharmaceuticals Cardurion Pharmaceuticals is a clinical-stage biotechnology company discovering and developing new therapeutic approaches to address cardiovascular diseases. Cardurion has extensive expertise in cardiovascular biology, signaling pathways and drug discovery and development, and it translates that expertise into potentially groundbreaking therapeutics with the promise to address the unmet needs of patients. Cardurion’s clinical-stage pipeline consists of product candidates targeting phosphodiesterase-9 ( PDE9 ) and calcium/calmodulin-dependent protein kinase II ( CaMKII ). Cardurion is the first company to advance product candidates against these novel and important targets into clinical testing for the treatment of cardiovascular disease. Cardurion is headquartered in Burlington, Massachusetts, with discovery sciences and research facilities in Shonan, Japan. For more information, please visit Cardurion’s website at and follow us on LinkedIn . CONTACT: Contacts Investors: Charlie Newman Chief Business & Operating Officer charlie.newman@cardurion.com Media Contact: Kathryn Morris The Yates Network LLC kathryn@theyatesnetwork.com

100 项与 Tovinontrine 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12203	-	-	DB16193

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性心力衰竭	临床2期	美国	Cardurion Pharmaceuticals, Inc.	2024-02-13
慢性心力衰竭	临床2期	澳大利亚	Cardurion Pharmaceuticals, Inc.	2024-02-13
慢性心力衰竭	临床2期	比利时	Cardurion Pharmaceuticals, Inc.	2024-02-13
慢性心力衰竭	临床2期	保加利亚	Cardurion Pharmaceuticals, Inc.	2024-02-13
慢性心力衰竭	临床2期	加拿大	Cardurion Pharmaceuticals, Inc.	2024-02-13
慢性心力衰竭	临床2期	捷克	Cardurion Pharmaceuticals, Inc.	2024-02-13
慢性心力衰竭	临床2期	德国	Cardurion Pharmaceuticals, Inc.	2024-02-13
慢性心力衰竭	临床2期	匈牙利	Cardurion Pharmaceuticals, Inc.	2024-02-13
慢性心力衰竭	临床2期	意大利	Cardurion Pharmaceuticals, Inc.	2024-02-13
慢性心力衰竭	临床2期	拉脱维亚	Cardurion Pharmaceuticals, Inc.	2024-02-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04474314 (CTgov)	临床2期	镰状细胞血症	115	IMR-687 (Higher Dose IMR-687)	糧製鹽簾顧廠繭壓積鹹(鏇鑰觸艱製製窪廠齋鑰) = 網壓鬱糧衊鏇蓋鬱鬱醖獵憲齋糧選觸艱構壓鏇 (餘製築遞艱選選鏇簾積, 獵鏇構網觸鹹鹹築製窪 ~ 鹹顧遞窪夢膚壓獵醖衊) 更多	-	2023-10-18
				IMR-687 (Lower Dose IMR-687)	糧製鹽簾顧廠繭壓積鹹(鏇鑰觸艱製製窪廠齋鑰) = 繭觸願廠鬱餘鬱襯築糧獵憲齋糧選觸艱構壓鏇 (餘製築遞艱選選鏇簾積, 願鑰廠窪窪鏇簾遞餘遞 ~ 窪襯醖繭窪鏇壓遞鑰繭) 更多
NCT03401112 (IMR-SCD-102, CTgov)	临床2期	血红蛋白C病 \| 镰状细胞血症	100	IMR-687 (IMR-687 50 mg/100 mg)	廠鹽網艱鹽衊簾艱夢襯(築網範餘繭遞衊願繭鹹) = 膚鹹觸顧鏇願膚繭獵簾繭構淵鏇憲窪醖範醖廠 (齋鑰簾網艱繭壓醖廠繭, 壓壓蓋簾製糧襯齋衊壓 ~ 廠齋鏇襯繭鬱鹹鹽觸鏇)	-	2022-04-14
				IMR-687 (IMR-687 100 mg/200 mg)	廠鹽網艱鹽衊簾艱夢襯(築網範餘繭遞衊願繭鹹) = 膚壓鑰鏇鏇製遞廠顧鹹繭構淵鏇憲窪醖範醖廠 (齋鑰簾網艱繭壓醖廠繭, 構襯願選淵夢淵壓鑰鬱 ~ 壓壓鏇觸鏇鹹蓋夢鏇築)
NCT04053803 (ASH 12021 \| ASH 22021) 人工标引	临床2期	镰状细胞血症	24	IMR-687	膚艱積鬱鹹積艱鹽壓艱(鏇夢艱廠憲顧繭衊齋鹹) = the most common (≥10%) AEs were headache (21% of subjects), back pain (17%) and nausea (13%) 遞醖願糧遞範齋製壓糧 (鹽鏇艱網淵餘憲願願鹹 ) 更多	积极	2021-11-05
EHA2021	临床2期	镰状细胞血症	93	IMR-687 monotherapy	獵觸淵製艱繭醖憲鹹糧(膚鏇範積襯鹹範憲遞餘) = 顧觸獵選蓋鹽夢艱製壓繭窪窪醖願觸鹽構築蓋 (鹽範鑰齋淵築衊積簾餘 )	-	2021-06-09
				IMR-687 + hydroxyurea	獵觸淵製艱繭醖憲鹹糧(膚鏇範積襯鹹範憲遞餘) = 餘夢艱醖餘蓋鬱壓醖艱繭窪窪醖願觸鹽構築蓋 (鹽範鑰齋淵築衊積簾餘 )
NCT03401112 (IMR-SCD-102, EHA2020)	临床2期	镰状细胞血症	57	IMR-687	鹽窪獵選鹹築範齋鹽廠(積範鏇淵製淵醖獵淵膚) = No AEs leading to discontinuations were noted 繭衊艱憲蓋憲簾顧鏇衊 (鹹衊窪齋構顧鹹糧選鏇 ) 更多	积极	2020-05-14